FDA (CBER)
GUIDANCE DRAFT
Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing
Published: 4/14/2026Detected: 4/14/2026
Summary preview
Topic: Status: Draft.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free account#Genome Editing
#Human Gene Therapy
#Next-Generation Sequencing
Official Source Document Source Verified
Access the original document directly from FDA CBER.
More from FDA (CBER)
- Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method9/16/2026
- Potency Assessment of Active Immunotherapy Products8/19/2026
- Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products: Guidance for Industry8/19/2026
- Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus: Guidance for Industry6/29/2026
- Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing6/2/2026